Vanadium Complexes with Hydrazone or Thiosemicarba... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents

Full text
Author(s):
de Souza, Paula C. [1] ; Maia, Pedro I. S. [2] ; de Barros, Heloisa B. [1] ; Leite, Clarice Q. F. [1] ; Deflon, Victor M. [2] ; Pavan, Fernando R. [1]
Total Authors: 6
Affiliation:
[1] Sao Paulo State Univ, Sch Pharmaceut Sci, BR-14801902 Araraquara, SP - Brazil
[2] Univ Sao Paulo, Inst Chem Sao Carlos, BR-13566590 Sao Carlos, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: CURRENT CLINICAL PHARMACOLOGY; v. 10, n. 1, p. 66-72, 2015.
Web of Science Citations: 1
Abstract

Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) and still an important public health problem worldwide. Some factors like the emergence of multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V) complexes were obtained upon reaction of {[}VO(acac)(2)] with hydrazone and thiosemicarbazone ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed asymmetrically oxo bridged binuclear complexes of the type {[}[VO(L-1,L-2)](2)(mu-O)(2)], involving the hydrazone ligands, while a mononuclear square pyramidal complex of the type {[}VO2(L-3)] was formed with the thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values between 2.00 and 3.76 mu M were considered promising for TB treatment. Such MIC values are comparable or better than those found for some drugs currently used in TB treatment. (AU)

FAPESP's process: 09/54011-8 - Acquisition of a single-crystal X-ray diffractometer for the structural analysis of small molecules and proteins
Grantee:Victor Marcelo Deflon
Support Opportunities: Multi-user Equipment Program
FAPESP's process: 13/14957-5 - Research potential against tuberculosis of a new class of furoxan compounds and nanostructured compounds of the ruthenium(II) and copper (II)
Grantee:Fernando Rogério Pavan
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 14/11586-9 - Studies in vitro and in vivo of furoxan compounds with potential application for the treatment of tuberculosis
Grantee:Paula Carolina de Souza
Support Opportunities: Scholarships in Brazil - Doctorate